spacer
home > epc > autumn 2003 > driving patient compliance
PUBLICATIONS
European Pharmaceutical Contractor

Driving Patient Compliance

The Scope of the Problem

Non-compliance commonly refers to the failure of patients to take medicines in their prescribed manner. Recognised as a serious health care issue, studies show that patient non-compliance can range from 20-80 per cent depending on the type of treatment being taken (1). The problem of non-compliance is not a new one and has been investigated for several decades worldwide.

The Consequences

Patient non-compliance lessens the quality of health care and can lead to dangerous consequences for patients. In the US, it has been estimated that non-compliance causes 340 deaths per day and is responsible for 10-25 per cent of hospital and nursing home admissions. Patient non-compliance is taken so seriously in the US that the New York Times dubbed it the nation's 'other drug problem' (2).

In a recent study conducted by Dendrite's Analytika Division, based on an analysis of data from nearly half of the US retail chain and independent companies, it was discovered that 'fewer than one in four patients on a cholesterol-lowering therapy completes a full year of treatment' (3). For the pharma industry, this gap between compliance and persistence translates into vast amounts of lost revenue.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Pietro Bonacossa, Marketing Executive, and Dr Faiz Kermani, Budgets, Proposals and Marketing Executive at Chiltern International Inc

Pietro Bonacossa is a Marketing Executive at Chiltern International in the USA. He holds a BA degree in International Trade from Auburn University and an MBA in Marketing from Georgia State University. Prior to joining Chiltern, he spent two years at Turner Broadcasting Systems, working as a Project Co-ordinator for CNN Headline News and as a Public Relations Liaison for CNN.com.


Dr Faiz Kermani is currently a Budgets, Proposals & Marketing Executive working in business development at Chiltern International. He previously worked in business development at CMR International, examining R&D productivity issues for pharmaceutical industry clients. He holds a PhD in Immunopharmacology from St Thomas' Hospital, London and a First Class honours degree in Pharmacology with Toxicology from King's College, London.


spacer
Pietro Bonacossa
spacer
spacer
spacer
Dr Faiz Kermani
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Wool packaging firm’s green scheme goes ‘beyond recycling’

An award-winning company that has spent more than 10 years innovating in sustainable packaging has launched a scheme that it says goes ‘beyond recycling’ – by allowing the end user to return their packaging directly to them to be used again.
More info >>

White Papers

Bringing more control to temperature-sensitive logistics

UPS Supply Chain Solutions

By 2016, world sales of cold-chain drugs and biologics such as vaccines and blood plasma products will near $240 billion1. The increase has led to a surge in discussion about how to protect these products throughout the transportation logistics cycle. Industry experts are recommending that the term “cold chain” be eliminated from rules, guidance and best-practice documents. “Cold chain” now includes a broader spectrum of temperature ranges, such as controlled room temperature (CRT). This white paper focuses on the initial steps required to establish a temperature-sensitive supply chain.
More info >>

 
Industry Events

Nordic Life Science Days 10/12 September 2019

10-12 September 2019, Malmo Sweden

Nordic Life Science Days is the largest Nordic partnering conference for the global Life Science industry. Bringing together the best talents in Life Science, offering amazing networking and partnering opportunities, providing inputs and content on the most recent trends. Nordic Life Science Days attracts leading decision makers from the Life Science sector, not only from biotech, pharma and medtech but also from finances, research, policy and regulatory authorities.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement